PPARG and Huntington disease: Despite these limitations, our study for the first time highlighted that the treatment of the HD mouse model with PPAR-γ agonists like rosiglitazone induces alterations in skeletal muscle and heart metabolism that may contribute to enhanced grip strength and improvement of cardiac function.